Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Fachpsychotherapie Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Journal of Nuclear Cardiology
Erschienen in:

06.05.2020 | REVIEW ARTICLE

Multimodality imaging approach to Fabry cardiomyopathy: Any role for nuclear cardiology?

verfasst von: Wanda Acampa, MD, PhD, Adriana D’Antonio, MD, Massimo Imbriaco, MD, Antonio Pisani, MD, Alberto Cuocolo, MD

Erschienen in: Journal of Nuclear Cardiology | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Anderson–Fabry disease (AFD) is a multisystem X-linked disorder of lipid metabolism frequently associated with progressive glycosphingolipid accumulation in cardiac, renal, and nervous cells. The diagnosis of AFD is usually assessed by enzyme assay and genetic tests, but advanced cardiac imaging can be useful in detecting early signs of the disease. Echocardiography and cardiac magnetic resonance are the first-line imaging modalities to investigate cardiac involvement in AFD, but the recent introduction of new molecular and hybrid imaging techniques opens to a wider range of diagnostic applications. This article aims to provide an overview of nuclear cardiology techniques in diagnosis and clinical management of AFD.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Desnick R, Ioannou Y, Eng C. Alpha-galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, et al., editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill; 2001. p. 3733-74.
2.
Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, et al. Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry. Mol Genet Metab. 2008;93:112-28.PubMedCrossRef
3.
Nordin S, Kozor R, Medina-Menacho K, Abdel-Gadir A, Baig S, Sado DM, et al. Proposed stages of myocardial phenotype development in Fabry disease. JACC Cardiovasc Imaging. 2019;12:1673-83.PubMedCrossRef
4.
Pisani A, Visciano B, Imbriaco M, Di Nuzzi A, Mancini A, Marchetiello C, et al. The kidney in Fabry’s disease. Clin Genet. 2014;86:301-9.PubMedCrossRef
5.
Perry R, Shah R, Saiedi M, Patil S, Ganesan A, Linhart A, et al. The role of cardiac imaging in the diagnosis and management of Anderson–Fabry disease. JACC Cardiovasc Imaging. 2019;12:1230-42.PubMedCrossRef
6.
Weidemann F, Sanchez-Nino MD, Politei J, Oliveira JP, Wanner C, Warnock DG, et al. Fibrosis: A key feature of Fabry disease with potential therapeutic implications. Orphanet J Rare Dis. 2013;8:116.PubMedPubMedCentralCrossRef
7.
Linhart A, Kampmann C, Zamorano JL, Sunder-Passmann G, Beck M, Mehta A, et al. Cardiac manifestations of Anderson–Fabry disease: Results from the international Fabry outcome survey. Eur Heart J. 2007;28:1228-35.PubMedCrossRef
8.
9.
Imbriaco M, Spinelli L, Cuocolo A, Maurea S, Sica G, Quarantelli M, et al. MRI characterization of myocardial tissue in patients with Fabry’s disease. Am J Roentgenol. 2007;188:850-3.CrossRef
10.
Imbriaco M, Pisani A, Spinelli L, Cuocolo A, Messalli G, Capuano E, et al. Effects of enzyme replacement therapy in patients with Anderson–Fabry disease: A prospective long-term cardiac magnetic resonance imaging study. Heart. 2009;95:1103-7.PubMedCrossRef
11.
Imbriaco M, Messalli G, Avitabile G, Cuocolo A, Maurea S, Soscia E, et al. Cardiac magnetic resonance imaging illustrating Anderson–Fabry disease progression. Br J Radiol. 2010;83:e249-51.PubMedPubMedCentralCrossRef
12.
Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G, et al. Identification and assessment of Anderson–Fabry disease by cardiovascular magnetic resonance non contrast myocardial T1 mapping. Circ Cardiovasc Imaging. 2013;6:392-8.PubMedCrossRef
13.
Thompson RB, Chow K, Khan A, Chan A, Shanks M, Paterson I, et al. T1 mapping with cardiovascular MRI is highly sensitive for Fabry disease independent of hypertrophy and sex. Circ Cardiovasc Imaging. 2013;6:637-45.PubMedCrossRef
14.
Hanneman K, Karur GR, Wasim S, Wald RM, Iwanochko RM, Morel CF. Left ventricular hypertrophy and late gadolinium enhancement at cardiac MRI are associated with adverse cardiac events in Fabry disease. Radiology. 2020;294:42-9.PubMedCrossRef
15.
Vijapurapu R, Nordin S, Baig S, Liu B, Rosmini S, Augusto J, et al. Global longitudinal strain, myocardial storage and hypertrophy in Fabry disease. Heart. 2019;105:470-6.PubMedCrossRef
16.
Spinelli L, Imbriaco M, Nappi C, Nicolai E, Giugliano G, Ponsiglione A, et al. Early cardiac involvement affects left ventricular longitudinal function in females carrying a-galactosidase A mutation: Role of hybrid positron emission tomography and magnetic resonance imaging and speckle-tracking echocardiography. Circ Cardiovasc Imaging. 2018;11:e007019.PubMedCrossRef
17.
Jamar F, Buscombe J, Chiti A, Christian PE, Donohoe KJ, Israel O, et al. EANM/SNMMI guideline for 18F-FDG use in inflammation and infection. J Nucl Med. 2013;54:647-58.PubMedCrossRef
18.
Nordin S, Kozor R, Bulluck H, Castelletti S, Rosmini S, Abdel-Gadir A, et al. Cardiac Fabry disease with late gadolinium enhancement is a chronic inflammatory cardiomyopathy. J Am Coll Cardiol. 2016;68:1707-8.PubMedCrossRef
19.
O h-Ici D, Ridgway JP, Kuehne T, Berger F, Plein S, Sivananthan M, et al. Cardiovascular magnetic resonance of myocardial edema using a short inversion time inversion recovery (STIR) black-blood technique: diagnostic accuracy of visual and semi-quantitative assessment. J Cardiovasc Magn Reson. 2012;28:14-22.
20.
Nappi C, Altiero M, Imbriaco M, Nicolai E, Giudice CA, Aiello M, et al. First experience of simultaneous PET/MRI for the early detection of cardiac involvement in patients with Anderson–Fabry disease. Eur J Nucl Med Mol Imaging. 2015;42:1025-31.PubMedCrossRef
21.
Imbriaco M, Nappi C, Ponsiglione A, Pisani A, Dell’Aversana S, Nicolai E, et al. Hybrid positron emission tomography magnetic resonance imaging for assessing different stages of cardiac impairment in patients with Anderson–Fabry disease: AFFINITY study group. Eur Heart J Cardiovasc Imaging. 2019;20:1004-11.PubMedCrossRef
22.
Toba M, Ishida Y, Fukuchi K, Shimotsu Y, Takamiya M, Komamura K, et al. Sympathetic reinnervation demonstrated on serial iodine-123-metaiodobenzylguanidine SPECT images after cardiac transplantation. J Nucl Med. 1998;39:1862-4.PubMed
23.
Verschure DO, Lutter R, van Eck-Smit BL, Somsen GA, Verberne HJ. Myocardial 123I-MIBG scintigraphy in relation to markers of inflammation and long-term clinical outcome in patients with stable chronic heart failure. J Nucl Cardiol. 2018;25:845-53.PubMedCrossRef
24.
Bertelsen AK, Tøndel C, Krohn J, Bull N, Aarseth J, Houge G, et al. Small fibre neuropathy in Fabry disease. J Neurol. 2013;260:917-9.PubMedCrossRef
25.
Alamartine E, Sury A, Roche F, Pichot V, Barthelemy JC. Autonomic nervous system activity in patients with Fabry disease. Open J Intern Med. 2012;2:116-22.CrossRef
26.
Imbriaco M, Pellegrino T, Piscopo V, Petretta M, Pellegrino T, Piscopo V, et al. Cuocolo, Cardiac sympathetic neuronal damage precedes myocardial fibrosis in patients with Anderson–Fabry disease. Eur J Nucl Med Mol Imaging. 2017;44:2266-73.PubMedCrossRef
27.
28.
Satoh K. Globotriaosylceramide induces endothelial dysfunction in Fabry disease. Arterioscler Thromb Vasc Biol. 2014;34:2-4.PubMedCrossRef
29.
Frustaci A, Russo MA, Francone M, Chimenti C. Microvascular angina as prehypertrophic presentation of Fabry disease cardiomiopathy. Circulation. 2014;130:1530-1.PubMedCrossRef
30.
Camici PG, Rimoldi OE. The clinical value of myocardial blood flow measurement. J Nucl Med. 2009;50:1076-87.PubMedCrossRef
31.
Assante R, Acampa W, Zampella E, Arumugam P, Nappi C, Gaudieri V, et al. Coronary atherosclerotic burden vs. coronary vascular function in diabetic and nondiabetic patients with normal myocardial perfusion: A propensity score analysis. Eur J Nucl Med Mol Imaging. 2017;44:1129-35.PubMedCrossRef
32.
Assante R, Acampa W, Zampella E, Arumugam P, Nappi C, Gaudieri V, et al. Prognostic value of atherosclerotic burden and coronary vascular function in patients with suspected coronary artery disease. Eur J Nucl Med Mol Imaging. 2017;44:2290-8.PubMedCrossRef
33.
Zampella E, Acampa W, Assante R, Nappi C, Gaudieri V, Mainolfi CG, et al. Combined evaluation of regional coronary artery calcium and myocardial perfusion by (82)Rb PET/CT in the identification of obstructive coronary artery disease. Eur J Nucl Med Mol Imaging. 2018;45:521-9.PubMedCrossRef
34.
Fiechter M, Ghadri JR, Gebhard C, Fuchs TA, Pazhenkottil AP, Nkoulou RN, et al. Diagnostic value of 13N-Ammonia myocardial perfusion PET: Added value of myocardial flow reserve. J Nucl Med. 2012;53:1230-4.PubMedCrossRef
35.
Slomka PJ, Alexanderson E, Jacome R, Jimenez M, Romero E, Meave A, et al. Comparison of clinical tools for measurements of regional stress and rest myocardial blood flow assessed with 13N-Ammonia PET/CT. J Nucl Med. 2012;53:171-81.PubMedCrossRef
36.
Murthy VL, Lee BC, Sitek A, Naya M, Moody J, Polavarapu V, et al. Comparison and prognostic validation of multiple methods of quantification of myocardial blood flow with 82Rb PET. J Nucl Med. 2014;55:1952-8.PubMedCrossRef
37.
Gaudieri V, Acampa W, Rozza F, Nappi C, Zampella E, Assante R, et al. Coronary vascular function in patients with resistant hypertension and normal myocardial perfusion: A propensity score analysis. Eur Heart J Cardiovasc Imaging. 2019;20:949-58.PubMedCrossRef
38.
Tomberli B, Cecchi F, Sciagrà R, Berti V, Lisi F, Torricelli F, et al. Coronary microvascular dysfunction is a nearly feature of cardiac involvement in patients with Anderson–Fabry disease. Eur J Heart Fail. 2013;15:1363-73.PubMedCrossRef
39.
Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human alpha-galactosidase: A replacement therapy in Fabry’s disease. New Engl J Med. 2001;345:9-16.PubMedCrossRef
40.
Schiffmann R, Kopp JB, Austin HA III, Sabnis S, Moore DF, Weibel T, et al. Enzyme replacement therapy in Fabry disease: A randomized controlled trial. JAMA. 2001;285:2743-9.PubMedCrossRef
41.
Vedder AC, Breunig F, Donker-Koopman WE, Mills K, Young E, Winchester B, et al. Treatment of Fabry disease with different dosing regimens of agalsidase: Effects on antibody formation and GL-3. Mol Genet Metab. 2008;94:319-25.PubMedCrossRef
42.
Germain DP, Fouilhoux A, Decramer S, Tardieu M, Pillet P, Fila M, et al. Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients. Clin Genet. 2019;96:107-17.PubMedPubMedCentralCrossRef
Metadaten
Titel
Multimodality imaging approach to Fabry cardiomyopathy: Any role for nuclear cardiology?
verfasst von
Wanda Acampa, MD, PhD
Adriana D’Antonio, MD
Massimo Imbriaco, MD
Antonio Pisani, MD
Alberto Cuocolo, MD
Publikationsdatum
06.05.2020
Verlag
Springer International Publishing
Erschienen in
Journal of Nuclear Cardiology / Ausgabe 3/2022
Print ISSN: 1071-3581
Elektronische ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-020-02124-1

Weitere Artikel der Ausgabe 3/2022

68Ga-FAPI right heart uptake in a patient with idiopathic pulmonary arterial hypertension

  • IMAGES THAT TEACH

Evolving use of PET viability imaging

  • EDITORIAL

Left ventricular ejection fraction, myocardial blood flow and hemodynamic variables in adenosine and regadenoson vasodilator 82-Rubidium PET

  • Original Article

Cardiac imaging for the assessment of patients being evaluated for liver transplantation

  • Review Article

Simultaneous measurements of myocardial glucose metabolism and extracellular volumes with hybrid PET/MRI using concurrent injections of Gd-DTPA and [18F]FDG

  • ORIGINAL ARTICLE

Evaluation of non-stenotic carotid atherosclerotic plaques with combined FDG-PET imaging and CT angiography in patients with ischemic stroke of unknown origin

  • ORIGINAL ARTICLE

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Kardiologie

Dank Nasenspray seltener in die Notaufnahme

Durch die intranasale Applikation von Etripamil lassen sich paroxysmale supraventrikuläre Tachykardien (PSVT) oft in Eigenregie beenden. Das erspart den Betroffenen das Aufsuchen von Notfallambulanzen.

Vorhofflimmern: So häufig kommt es bei Katheterablation zu Embolien

Arterielle Embolien – insbesondere Hirnembolien - sind eine mögliche periprozedurale Komplikation bei Katheterablation von Vorhofflimmern. Wie hoch ist das Risiko? Eine Analyse von weltweit mehr als 300.000 Ablationsprozeduren gibt darüber Auskunft.

Extrakorporale Reanimation: Wechsel des EKG-Musters verschlechtert Prognose

Patientinnen und Patienten im Herzstillstand mit schockbarem Rhythmus, deren EKG-Muster sich später ändert, haben schlechtere Chancen. Eine Studiengruppe hat die Bedeutung eines solchen Rhythmuswechsels mit Blick auf die extrakorporale Reanimation genauer untersucht.

Leben retten dank Erste-Hilfe-App

Bei einem Herzstillstand zählt jede Minute bis eine Reanimation begonnen wird. Notfallmediziner Prof. Dr. med. Michael Müller erklärt im Interview, wie medizinisch geschulte Ersthelfende mittels App alarmiert werden können – und warum digitale Lösungen die Notfallversorgung revolutionieren könnten.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise